NovaBridge Biosciences
Business
NovaBridge Biosciences is a global biotechnology company focused on developing precision immuno-oncology agents for the treatment of cancer. It develops and advances a clinical-stage pipeline of biotherapeutics, including bispecific antibodies givastomig (CLDN18.2 x 4-1BB), uliledlimab (CD73 antibody), and ragistomig (PD-L1 x 4-1BB), and supports companion diagnostic development and biologics manufacturing strategies. Its business is organized around global drug development, collaboration and licensing arrangements, and manufacturing/supply relationships, including partnerships with ABL Bio and Bristol-Myers Squibb. It conducts clinical trials and commercialization activities across the United States, Europe, Japan and Greater China (with certain Greater China assets divested) and distributes through clinical networks, partners and contract manufacturers.
Summary from filing dated 2025-04-03
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-46.27M |
| Total assets | $260.52M |
| Total liabilities | $29.58M |
| Stockholders' equity | $230.94M |
| Operating cash flow | $-20.60M |